Abstract

Abstract This meta-analysis examines the cardiovascular safety of long-term biologic therapy use across various autoimmune and inflammatory conditions. Through systematic review and analysis of clinical trial data, we investigate the incidence of cardiovascular events, including myocardial infarction, stroke, and heart failure, among patients receiving biologic therapies compared to controls. Despite concerns regarding the potential cardiovascular risks associated with chronic inflammation and biologic therapy use, our comprehensive analysis reveals no significant increase in cardiovascular events with long-term biologic therapy use. These findings offer reassurance regarding the cardiovascular safety of biologic therapies in the management of autoimmune and inflammatory conditions, though ongoing monitoring and comprehensive cardiovascular risk management remain essential.